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Neurons in Huntington’s disease exhibit selective morphologi-
cal and subcellular alterations in the striatum and cortex. The
link between these neuronal changes and behavioral abnormal-
ities is unclear. We investigated relationships between essential
neuronal changes that predict motor impairment and possible
involvement of the corticostriatal pathway in developing behav-
ioral phenotypes. We therefore generated heterozygote mice
expressing the N-terminal one-third of huntingtin with normal
(CT18) or expanded (HD46, HD100) glutamine repeats. The HD
mice exhibited motor deficits between 3 and 10 months. The
age of onset depended on an expanded polyglutamine length;
phenotype severity correlated with increasing age. Neuronal
changes in the striatum (nuclear inclusions) preceded the onset
of phenotype, whereas cortical changes, especially the accu-
mulation of huntingtin in the nucleus and cytoplasm and the
appearance of dysmorphic dendrites, predicted the onset and
severity of behavioral deficits. Striatal neurons in the HD mice
displayed altered responses to cortical stimulation and to acti-
vation by the excitotoxic agent NMDA. Application of NMDA
increased intracellular Ca2 levels in HD100 neurons compared
with wild-type neurons. Results suggest that motor deficits in
Huntington’s disease arise from cumulative morphological and
physiological changes in neurons that impair corticostriatal
circuitry.
Key words: cortex; Huntington’s disease; NMDA; neuronal
morphology; striatum; transgenic mice
Huntington’s disease is a fatal autosomal dominant neurodegen-
erative disease characterized by movement abnormalities, psychi-
atric disturbances, and dementia (Huntington, 1872). The gene
mutation in Huntington’s disease comprises a lengthening of a
series of CAG repeats beyond 35 in a gene encoding a protein
called huntingtin (Huntington’s Disease Collaborative Research
Group, 1993). Although mutant huntingtin has a widespread
distribution in neuronal and non-neuronal tissues, neurons in the
striatum and cortex layers 3, 5, and 6 demonstrate characteristic
cellular and subcellular pathological changes, including formation
of nuclear inclusions and dystrophic neurites containing
N-terminal mutant huntingtin (Vonsattel et al., 1985; DiFiglia et
al., 1997; Vonsattel and DiFiglia, 1998).
In murine models of Huntington’s disease the cellular features
differ among transgenic models and from morphological changes
observed in the Huntington’s disease patient brain. Mice express-
ing very truncated transgenes develop widespread nuclear inclu-
sions (Davies et al., 1997; Schilling et al., 1999), far more than
exist in the HD patient brain (DiFiglia et al., 1997). Mice with
full-length mutant huntingtin have fewer inclusions than in the
human condition (Reddy et al., 1998; Hodgson et al., 1999).
Striatal cell loss, a hallmark of change in the patient brain, is not
striking in most Huntington’s disease mouse models, except in
some older mice with full-length mutant huntingtin that are
hypokinetic or akinetic (Reddy et al., 1998, 1999). Still, current
murine models of Huntington’s disease manifest behavioral
changes. Thus, neuronal dysfunction as implicated by abnormal
neuronal morphology, and not cell death, might underlie move-
ment abnormalities in Huntington’s disease.
To address these issues, we generated transgenic mice with 18,
46, and 100 CAG repeats in a human huntingtin cDNA that
encoded the first one-third of the huntingtin protein. The CAG
repeat lengths are consistent with the normal human (18), adult
form of Huntington’s disease (46), and the juvenile form (100).
This size of huntingtin protein causes the same cellular pathology
as full-length mutant huntingtin in transfected clonal medium
spiny neurons (Kim et al., 1999; Kegel et al., 2000). The morpho-
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logic and subcellular abnormalities in vitro mimic those in stria-
tum and cortex in Huntington’s disease. Thus, we have evidence
that this portion of huntingtin with an expanded polyglutamine
repeat is sufficient to reproduce morphological changes of Hun-
tington’s disease.
On the basis of morphological, behavioral, and electrophysio-
logical evidence from our transgenic murine model of Hunting-
ton’s disease, changes in cortical neurons, including nuclear and
cytoplasmic accumulation of huntingtin and the appearance of
dysmorphic dendrites, were correlated the most closely with the
onset of motor deficits. Striatal neurons in transgenic mice had
marked alterations in electrophysiological responses to corpus
callosum stimulation (corticostriatal pathway) and in the activa-
tion of NMDA receptors. Thus, we propose that the effects of
mutant huntingtin on cortical neurons play a critical role in
striatal neuronal dysfunction in Huntington’s disease and in its
neurologic impairment.
MATERIALS AND METHODS
Transgene design
The initial 3 kb of the human huntingtin-encoding cDNA sequence IT15
(Huntington’s Disease Collaborative Research Group, 1993) were
cloned into transfer plasmid AcMNPV downstream from the rat neuron-
specific enolase promoter and its first intron (Fig. 1 A). An eight-amino-
acid FLAG epitope tag was included just 5 to the IT15 sequence to
permit immunologic detection of the transgene. Three different CAG
repeat lengths, 18, 46, and 100, were inserted into the sequence. The
construct included an SV40 polyadenylation signal. The full 3 kb length
of the IT15 cDNA used in the transgene was sequenced.
Generation and genotyping of transgenic mice
Transgene DNA for microinjection was treated with PacI, purified, and
used to microinject oocyte pronuclei from C57BL/6SJL F1 hybrid mice.
Transgenic mice were generated and maintained in the Transgenic Core
Facility at the University of Massachusetts Medical School. Genomic
DNA from F0 mice was extracted from tail biopsies and characterized
initially by Southern blot analysis, using a cDNA IT15 probe. After
transgene-positive founders were identified, lineages were screened by
Southern blot or PCR analysis. Estimation of transgene insertion site and
copy number followed the procedure of Reddy et al. (1998).
Detecting expression of the huntingtin transgene
Evidence for transcription of the transgene was provided by analysis of
total RNA in Northern blots and RT-PCR. Western blot analysis was
performed as reported previously (Aronin et al., 1995).
Behavioral analysis
All transgenic animals were maintained in microisolator cages with free
access to food and water under pathogen-free conditions in a 12 hr
light /dark cycle in the Animal Medicine Facility at the University of
Massachusetts Medical School. After weaning, the males were housed
singly, and the female littermates were housed grouped. Care and han-
dling of experimental animals complied fully with institutional, Society
for Neuroscience, and federal guidelines for humane treatment. Behavioral
analyses were performed in the mornings, circadian time CT 1–6 hr.
Animals were evaluated neurologically with four tests: rotarod perfor-
mance, clasping, activity level, and gait. Evaluation of clasping, activity
level, and gait were subjective. Two observers tested 474 mice so that the
testing procedures would be performed consistently. We cannot state
with certainty that the observers did not know or suspect the HD
genotype, because WT mice rarely displayed behavioral changes under
12 months of age. We used only robust changes in clasping, activity, and
gait to minimize observer bias. Observations were made at the same
examination to minimize age as a variable.
Rotarod performance. This analysis used a rotarod apparatus
(Economex Rotarod, Columbus Instruments, Columbus, OH) to assess
the ability of the animals to stay on a rotating rod through successive 2
min trials at increasing speeds. The mice were pretrained on the rotarod
for five trials at low speed (214 cm/min) for up to 120 sec. Animals then
were tested for one trial each at medium (277 cm/min) and high speed
(340 cm/min). The rotarod score (0–120 sec) equaled the mean number
of seconds the animal stayed on the rotarod at low speed averaged with
the mean of the two higher speed trials. For inclusion in the hazard
analysis, rotarod scores of 60 sec were considered abnormal. Rotarod
scores had a bimodal distribution, with clusters of HD mice below 60 sec
and with control and wild-type mice above 60 sec. To validate our
rotarod protocol, we tested 181 different mice (wild type, CT18, HD46,
and HD100) in the rotarod protocol of Clark et al. (1997) and found no
differences in the rotarod results when compared with our method.
Clasping. Mice were held suspended by the tail for up to 1 min at a
height of 15 cm. Clasping was defined as grabbing forepaws alone or
forepaws and hindlimbs simultaneously. A presence of clasp required
paws to be pressed against the chest with the spine in a lordotic position.
Clasp was scored as its presence or absence.
Activity level. Hyperactivity was defined as circling or rapid to-and-fro
movement, also known as stereotypic behavior. Hypoactivity was defined
as paucity of spontaneous movement. The mice were not perturbed to
elicit activity. If an animal did not meander voluntarily in the cage, the
observer picked up the cage, which was sufficient to elicit meandering in
most mice. Activity was scored as the presence or absence of hypoactivity
or hyperactivity.
Gait. Abnormal gaits included wide-based gait, walking with an arched
posture, or slow gait with tremulousness. Gait was scored as the presence
or absence of an abnormal gait. For emphasis, only robust changes in
clasping, activity, or gait would be detected with the scoring of these
behaviors.
Morphological analysis
Immunohistochemistry antibodies. Anti-huntingtin rabbit antisera were
made with the N terminus of huntingtin (Ab1) and an internal epitope of
huntingtin (Ab585; amino acids 585–725). Both antisera were character-
ized as reported previously (DiFiglia et al., 1995).
Immunohistochemical procedure. After perfusion with 4% paraformal-
dehyde in PBS, the brains of the mice were removed, post-fixed in
paraformaldehyde, and sectioned at 40 m. A series of treatments with
primary antiserum, biotinylated anti-rabbit antiserum, and avidin–biotin
horseradish peroxidase complex followed. The chromogen was diamino-
benzidine. Details were described by DiFiglia et al. (1995). Controls
included omission of primary antisera and competitive incubation with
10 g of huntingtin peptide.
Light microscopy. Examination of brain sections was performed with-
out previous knowledge of the genotype or phenotype of mice.
Cell counts and cross-sectional area measurements. The cell counts were
obtained in seven wild-type controls (mean age, 9.4 months, range 3–17
months), three CT18 mice (all 18 months), and seven HD100 mice (mean
age, 8.7 months, range 3–17 months), using a stereological method
described by Hyman et al. (1998). Briefly, 40 m sections were cut
through the entire striatum and stained with cresyl violet; every sixth
section was assessed, totaling 10–12 sections per striatum. At 1000
magnification, all neurons in 100  100 m fields were counted in every
sixth field throughout the section. In all, 50–60 fields were counted for
each brain from which an average and SD were determined. For mea-
surement of cross-sectional area, digital computer images of 25 striatal
neurons per mouse were acquired through the microscope with a 100
objective lens and Sigma Scan software (Jandel Scientific, San Rafael,
CA). The mean values from five controls (three wild type and two CT18)
and six HD mice (five HD100 and one HD46) were analyzed with a
two-tailed Student’s t test. The ages of the controls (11 months 2.4) and
the HD mice (8.1 months  4.8) were not significantly different.
Assessment of dendrite morphology in biocytin-filled neurons. To provide
a set of unbiased estimates, three observers, who were blinded to the
genotype from which the neurons were obtained, counted J-dendrites
and wavy dendrites in all recovered cells on a set of qualitative scales (for
J-dendrites: 0  dendrites extend normally, 1  one or two dendrites
begin to turn, 2  one or two dendrites make close to a complete turn,
and 3  three or more dendrites make close to a complete turn; for wavy
dendrites: 0  dendrites extend normally, 1  one or two have moder-
ately wavy dendrites, 2  two or three have obviously wavy dendrites,
3  three or more dendrites have obvious waviness, 4  there are many
wavy dendrites, some severe, and 5  almost all dendrites are severely
wavy). There was a high counting reliability for both measures.
Electrophysiology
Slice preparation. Preparation of tissue was similar to procedures de-
scribed previously (Cepeda et al., 1998; Levine et al., 1999). Twenty-six
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mice (17 HD100 and 9 WT) were used for electrophysiology. The mice
were decapitated. After dissection the brains were placed in ice-cold
oxygenated artificial CSF (aCSF) [containing (in mM) 130 NaCl, 26
NaHCO3, 3 KCl, 5 MgCl2, 1.25 NaH2PO4, 1 CaCl2, and 10 glucose, pH
7.2–7.4]. Coronal brain sections containing the striatum were cut (350
m) and placed in oxygenated aCSF, but with 2 mM each CaCl2 and
MgCl2. After 1 hr the slice was transferred to a recording chamber.
Current clamp. In the recording chamber the slices were perfused
constantly with oxygenated aCSF [containing (in mM) 124 NaCl, 2
MgSO4, 2 CaCl2, 5 KCl, 1.25 NaH2PO4, 26 NaHCO3, and 10 glucose at
31–32°C, with 50 M picrotoxin to block the responses mediated by
activation of GABAA receptors] in an atmosphere of warm, moist 95%
O2/5% CO2. Responses of individual cells were recorded by sharp
microelectrodes filled with 3 M K-acetate, 5 mM KCl, and 2% w/v
biocytin (Sigma, St. Louis, MO) to label dendritic and axonal processes.
After the experiment the slice was fixed in 4% paraformaldehyde over-
night and processed according to published protocols (Kita and Arm-
strong, 1991). Resting membrane potentials were recorded only after the
cell had recovered from penetration and had stabilized (at least 15 min
after impalement). The current–voltage relationship was determined
from the responses to incrementally increasing square wave hyperpolar-
izing and depolarizing current pulses delivered via the recording elec-
trode. To examine synaptic responses, we placed a bipolar stimulating
electrode in the corpus callosum to activate the corticostriatal fibers
preferentially. Stimuli (100 sec duration, variable intensity from 100 A
to 5 mA) were delivered every 5 sec, and input–output relationships were
determined. Responses were averages of five traces.
Whole-cell voltage clamp. Neurons were visualized in the slice with a
fixed-stage upright microscope (Olympus, Model BX50WI) and sub-
merged in continuously flowing oxygenated aCSF (25°C, 4 ml/min).
Cells were visualized with a 40 water immersion lens that used differ-
ential interference contrast optics and were illuminated with near-
infrared light (790 nm; Ealing Optics, Holliston, MA). The image was
detected with an infrared-sensitive CCD camera. Patch electrodes (3–6
M) were filled with the following internal solution (in mM): 130 Cs-
methanesulfonate, 10 CsCl, 4 NaCl, 1 MgCl2, 5 Mg-ATP, 5 EGTA, 10
HEPES, 0.5 GTP, 10 phosphocreatine, and 0.1 leupeptin, pH 7.25–7.3,
with an osmolality of 280–290 mOsm. An Axopatch 200A (Axon Instru-
ments, Foster City, CA) was used for recording. A 3 M KCl agar bridge
was inserted between the extracellular solution and the Ag–AgCl indif-
ferent electrode. Tight seals (2–5 G) from visualized medium-sized
cells were obtained by applying negative pressure. Recordings were not
corrected for junction potentials, which ranged from 2–3 mV. Leak
subtraction was performed on-line with the Axopatch 200B amplifier.
The membrane was disrupted with additional suction to obtain the
whole-cell configuration. Access resistances ranged from 10 to 25 M
and were compensated 60–85%. Cells were held at70 mV to minimize
contributions of voltage-gated currents. Voltage-gated currents also were
blocked with the following solution: 1 M tetrodotoxin (TTX), 100–200
M Cd 2, 3 mM Cs, 20 mM tetraethylammonium (TEA), and 2 mM
4-aminopyridine (4-AP). NMDA was bath applied to the striatal slice.
Non-NMDA receptor activation was blocked with 6-cyano-7-
nitroquinoxaline-2, 3-dione (CNQX; 5 M). Cell capacitances and input
resistances were measured by applying a 10 mV depolarizing voltage
command and by using the membrane test function integrated in the
pClamp8 software (Axon Instruments).
Statistical analysis
For the behavioral analysis, logistical regression (Draper and Smith,
1998) was used when behaviors were ranked as the presence or absence
Figure 1. Design and expression analysis of transgenes CT18, HD46,
and HD100. A, Map of construct used for transgene vector. Bases 316–
3210 of the human huntingtin cDNA sequence (IT15), modified to con-
tain 18, 46, or 100 CAG repeats, were cloned into AcMNPV transfer
plasmid NSE4-BV. A rat neuron-specific enolase promoter regulates
expression. An N-terminal epitope tag, FLAG, was included to permit
differential identification of the transgene-encoded huntingtin product.
Northern blot and RT-PCR analyses confirm RNA expression from
CT18, HD46, and HD100 transgenes. B, The Northern blot demonstrates
transgene expression in different HD46 and HD100 lineages (denoted
above the lanes). B, Left and Top right, Total RNA (10 g) per lane.
B, Bottom right, Total RNA (30 g) per lane. An arrowhead (Œ) marks
the bands corresponding to transgene-encoded RNA. Wild-type con-
trol lanes show no transgene-derived message. C, RT-PCR results from
4
CT18, HD46, and HD100 lineages. Lane M, A 100 base pair ladder; lane
C, no RNA control. An arrowhead (Œ) marks the position of the expected
RT-PCR product. Expression is seen in all transgenic lineages but is
absent from the transgene-negative (WT ) control. D, Western blot anal-
ysis of huntingtin (top) and FLAG (bottom) immunoreactivity in WT,
CT18, HD46, and HD100 mice. D, Top, A product of the expected size
(	120 kDa, black arrowhead) is present in the transgenic mice, but not in
WT. Native huntingtin is denoted with a white arrow. The signal intensity
for the 	120 kDa product is stronger in the HD mice compared with CT.
Huntingtin is detected with antiserum Ab1. D, Bottom, A product of the
expected size (	120 kDa, black arrow) is present in the transgenic mice,
but not in WT.
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of an abnormality (clasping, activity, gait). Linear regression (Draper
and Smith, 1998) was used for rotarod tests. In analyses in which the
number of abnormalities in each mouse was examined, we converted the
rotarod to the presence or absence of abnormality. Rotarod tests were
distributed in a bimodal pattern. The range spanned 48–78 sec between
the two modes. We selected 60 sec as the cutoff for a normal rotarod test.
A hazard score was used to compare the rates at which subsets of mice
developed behavioral abnormalities. Hazard score is a rate that assesses
the short-term conditional probability of developing an abnormality. The
rate over a particular time interval is calculated by using the number of
mice in subsets (WT and CT18 vs HD46 and HD100) becoming abnor-
mal over that interval, conditional on the number of animals that re-
mained healthy at the beginning of the interval (Collett, 1994). To
determine possible correlations between behavioral deficits and neuro-
pathological findings, we used the CORR procedure (SAS statistical
analysis software; SAS Institute, Cary, NC) to generate Pearson corre-
lation coefficients. For analysis of electrophysiological changes, Welch’s
approximation to the t test for unequal variances (Welch, 1947) and
ANOVA with Bonferroni correction were used.
RESULTS
Verification of mice with huntingtin transgenes
Southern blot analysis confirmed insertion of mutant (HD) and
wild-type (CT) huntingtin transgenes into the mouse genome
(transgene map shown in Fig. 1A). Multiple lineages with 18, 46,
and 100 CAG repeat lengths were identified. The lineages had a
range of copy numbers, estimated from 1–52 (CT18: 1, 5; HD46:
11, 15, 23, 52; HD100: 3, 5, 6, 10, 11, 12), and different insertion
sites (data not shown). As detected by Northern blot analysis (Fig.
1B) and RT-PCR (Fig. 1C), RNA expression demonstrated trans-
gene transcription. Western blot analysis that used anti-
huntingtin and anti-FLAG antisera confirmed the presence of a
protein of the expected size for the transgene product (	120
kDa) (Fig. 1D). Protein expression in Western blot was less than
that of native huntingtin and variable in the HD mice. Immuno-
histochemistry with anti-FLAG and anti-huntingtin antibodies
detected nuclear inclusions and other changes in the HD mice,
consistent with the expression of the mutant transgene (see
below).
Mutant huntingtin transgenes promote
neurological impairments
We studied 474 mice, distributed as wild type (n  110) and
transgenics with 18 CAG (CT18, n  30), 46 CAG (HD46, n 
146), and 100 CAG (HD100, n  188). Animals were tested from
all lineages and from generations up to F6. Neither lineage nor
copy number influenced the neurological outcomes. Age had a
separate but weak effect on neurological outcomes ( p  0.05).
Neurological outcomes were scored as normal versus abnormal
for clasping, gait, and activity; significance was tested by logistic
regression. The performance in staying on the rotarod was scored
in seconds, and linear regression was used for statistical analysis.
There was no significant difference between wild-type mice and
CT18 mice for any of the neurological tests. Compared with wild
type or CT18, HD46 showed differences in clasping ( p  0.001),
gait ( p  0.05), activity ( p  0.001), and rotarod ( p  0.001).
HD100 mice also demonstrated a difference in each neurological
test ( p  0.001 for each).
The frequency of the number of neurological abnormalities
also was evaluated in a 2 distribution, regardless of age (Table
1). Approximately 80% of the wild-type and CT18 mice had no
neurological impairment, whereas 60% of the HD46 mice and
72% of the HD100 mice had at least one abnormality. Further-
more, the HD46 and HD100 were more likely to have more than
one abnormal neurological test.
To determine the rate at which neurological impairments pre-
sented, we generated a hazard score. A hazard score is the
measurement of change in behavior as a function of time. In this
formulation the test outcome was either normal or abnormal.
Rotarod scores of 60 sec were considered abnormal (derivation
in Materials and Methods). Figure 2 shows that for both wild-type
and CT18 mice there is little likelihood of developing a behav-
ioral abnormality for the first 12 months of life, but the rate of
developing neurological deficits increases after 12 months. How-
ever, the HD46 and the HD100 transgenic mice demonstrate an
increase in the rate of developing an abnormality by 3 months.
The rate increases through the lifespan of the population of mice.
Neuropathological changes in the HD mice:
accumulation of huntingtin, dysmorphic dendrites,
vacuoles, membrane blebs, and atrophy
We evaluated the localization of huntingtin in HD, CT18, and
WT mice. Huntingtin staining detected with Ab1 and Ab585
antisera was increased markedly in the somatodendritic cyto-
plasm of cortical and striatal neurons of HD46 (n  9) and
Table 1. Number of neurological abnormalities in WT, CT18, HD46,
and HD100 mice: 2 analysis
Number of
abnormalities WT CT18 HD46* HD100*
0 78.2 (86) 80.0 (24) 39.7 (58) 27.7 (52)
1 17.3 (19) 20.0 (6) 42.5 (62) 52.7 (99)
2 3.6 (4) 0 (0) 10.3 (15) 16.0 (30)
3 0.9 (1) 0 (0) 5.5 (8) 3.2 (6)
4 0 (0) 0 (0) 2.1 (3) 0.5 (1)
HD46 and HD100 groups have a significantly higher percentage of mice with one or
more neurological abnormalities than do WT or CT18 mice. The percentage of
animals in each group (WT, CT18, HD46, and HD100) having 0, 1, 2, 3, or 4
neurological deficits is shown in each column. The actual numbers of affected
animals in each category are shown in parentheses. 2 analysis demonstrates that
HD46 and HD100 groups (asterisks) have a significantly higher percentage of
animals with single or multiple deficits than do WT or CT18 ( p  0.001).
Figure 2. Hazard score for WT/CT18 versus HD46/HD100. Hazard
scores calculate the rate of development of neurological deficits over time.
Mice with normal polyglutamine length (WT, CT18 ) were compared
with transgenics with expanded polyglutamines (HD46, HD100 f). WT
and CT18 have a near-zero hazard rate for the first 12 months; the rate
rises thereafter, suggesting late development of severe symptoms. Con-
versely, the hazard rate for HD46 and HD100 begins to increase in the
first month and continues to climb, indicating that phenotypic expression
of HD transgenes with expanded polyglutamines begins early and in-
creases with age.
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HD100 (n  26) compared with CT18 (n  6) and WT (n  4)
mice (Fig. 3a). Cortical pyramidal neurons in the HD mice had
dysmorphic dendrites, which were characterized by marked re-
traction and disorientation of the apical dendrite (Fig. 3b–d).
Cytoplasmic huntingtin accumulation and dysmorphic changes
were seen in the cortex of all HD lineages, were especially
prevalent in frontal and cingulate cortices, and occurred variably
and infrequently in piriform and hippocampal cortices. Intracy-
toplasmic vacuoles and plasma membrane blebs appeared in cell
bodies and dendrites of some of the HD neurons that had a
cytoplasmic accumulation of huntingtin (Fig. 3e). Dysmorphic
dendrites were not present in hippocampal pyramidal neurons of
five of eight mice examined, were sparse in two mice, and exten-
sive in a severely affected mouse. This severely affected mouse
also showed dysmorphic dendrites in some cerebellar Purkinje
cells and shrunken neurons in hippocampus and cerebellum.
Except for the most severely affected HD mouse, other brain
regions known to be relatively uninvolved at early stages of
Huntington’s disease had no or mild neuropathological changes
when compared with cortex and striatum. Thus, dysmorphic den-
drites were not evident in other brain regions of most HD mice,
despite increased somatodendritic cytoplasmic labeling for hun-
tingtin in the neurons there.
Huntingtin labeling in neuronal nuclei was widespread in layers
2/3, 5, and 6 of the cortex and throughout the striatum of HD46
and HD100 mice, but not of CT18 and WT mice (Figs. 4a, 5a,b).
The proportion of neurons with diffuse nuclear labeling was
significantly greater (Student’s t test, p  0.0001) in the striatum
(mean, 80% of neurons) than in the cortex (mean, 43% of
neurons; see Fig. 6A, top). Intranuclear inclusions were detected
in most HD46 and HD100 mice (Figs. 4b, 5d–f) with anti-
huntingtin antisera Ab1 and Ab585 as well as with anti-ubiquitin
and anti-FLAG antisera in some of the older, more severely
affected mice (Fig. 5e,f). Ab1 robustly detects inclusions in cor-
tical and striatal neurons of Huntington’s disease brain and in
other transgenic mouse models (Davies et al., 1997; Levine et al.,
1999). Ab585 detects inclusions in the cortex of some Hunting-
ton’s disease brains (Sapp et al., 1999) and in clonal striatal cells
after overexpression of truncated or full-length mutant hunting-
tin (Kim et al., 1999). In parallel with Huntington’s disease
juvenile and adult-onset patients (Sapp et al., 1997; Gutekunst et
al., 1999), neurons with inclusions were more frequent in the
cortex and striatum of HD100 mice (mean, 23%) than in the
cortex and striatum of HD46 mice (mean, 7%). Inclusions were
significantly more frequent in the cortex (mean, 19% of neurons)
than in the striatum of HD mice (mean, 6% of neurons; Student’s
t test, p  0.01; Fig. 6A, bottom), a characteristic also noted in
adult-onset Huntington’s disease brain (Sapp et al., 1999). Neu-
rons with inclusions also had prominent, diffuse staining for
Figure 3. Increased huntingtin immunoreactivity and dysmorphic den-
drites in HD mice. a, WT mouse (8.5 months, rotarod, normal behavior)
exhibits low to moderate levels of huntingtin labeling in the cytoplasm
and proximal dendrites of pyramidal neurons. b–e, HD mice have intense
labeling for huntingtin in the cytoplasm and proximal dendrites (b,
HD100, L63, 4.5 months, RR  10, clasp; c, HD46, L17, 12 months,
RR  66, clasp; d, HD100, L63, 7 months, RR  51; e, HD100, L46, 12
months, RR  26). Some neurons also show diffuse nuclear staining (d).
Dysmorphic dendrites show marked retraction (arrows in c, d) and dis-
orientation (arrowhead in d). Membrane blebbing occurs in cell bodies
and dendrites (arrow in e). Staining was performed with anti-huntingtin
antibody Ab585. Scale bars: a, b, 25 m; c–e, 10 m.
Figure 4. Cortical neurons with huntingtin immunoreactivity in HD
mice. a, HD46 mouse (L14, 14 months, RR  14, clasp, hypoactive,
broad-based gait) has diffuse nuclear huntingtin labeling in layer 5 pyra-
midal neurons. Some neurons have marked blebbing of the plasma mem-
brane (arrows). b, Nuclear inclusions in pyramidal cells of HD100 mouse
(L59, 7 months, RR  15, clasp). One of the neurons (top) also has
diffuse nuclear labeling. c, d, Layer 6 from a transgenic control mouse
with 18 glutamines in huntingtin (c, L3, 7 months, normal behavior) and
an HD100 mouse (d, L59, 7 months, RR  15, clasp). Compared with
the neurons in c, the neurons in d are reduced in size and show increased
huntingtin immunoreactivity in nuclei. cc, Corpus callosum. Staining for
huntingtin was performed with antibody Ab585. Scale bars: a–d, 25 m.
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huntingtin in the nucleus (20–30% of neurons with inclusions)
and cytoplasm (98% of neurons with inclusions).
Both medium-sized and large striatal neurons had inclusions.
Large neurons, which account for only 1–2% of all striatal neu-
rons and generally are spared in Huntington’s disease, had a
much higher frequency of inclusions than medium-sized cells. In
an analysis of five HD100 mice (ages 3–11 months) with normal
and abnormal behaviors, 27–70% of the large striatal neurons that
labeled for huntingtin had intranuclear inclusions (mean, 47%).
Electron microscopic analysis revealed that the nuclear inclusions
formed in the cortex and striatum of HD mice were composed of
granules and filaments (results not shown) and appeared to be
similar to those seen in Huntington’s disease brain (DiFiglia et
al., 1997).
Huntingtin-immunoreactive neurons appeared smaller or re-
duced in number in the striatum (Fig. 5b) and in layer 6 cortex
(Fig. 4c,d) in the majority of the HD mice. Measurements of
cross-sectional area showed that huntingtin-immunoreactive stri-
atal neurons in the HD mice were significantly smaller than in
Figure 6. Quantitative assessment of dysmorphic dendrites, diffuse nu-
clear labeling, nuclear inclusions, and cell density in relation to phenotype.
A, Diffuse nuclear labeling and neuronal intranuclear inclusions in cortex
and striatum. Mice are identified by HD type (46 or 100) and age (months)
on the abscissa. A, Top, Neurons with diffuse nuclear labeling for huntingtin
in the cortex and striatum of HD46 and HD100. RR score is shown at the
top of the bars, from highest to lowest. There are significantly more neurons
with diffuse nuclear labeling in the striatum than in the cortex ( p  0.01).
Impaired rotarod performance is correlated positively with the extent of
diffuse nuclear labeling in the cortex ( p 0.03), but not in the striatum. A,
Bottom, Intranuclear inclusions in the cortex and striatum in the same set of
HD mice. Inclusions are significantly more frequent in the cortex than in
the striatum ( p  0.01) and are correlated with better rotarod scores ( p 
0.004). B, Extent of dysmorphic morphology in huntingtin-labeled cortical
neurons of control and HD46 and HD100 mice (J-dendrites, wavy den-
drites) versus rotarod performance. A rating scale (0, 1, 2) for dysmor-
phic dendrites was used (see Materials and Methods), with 2 assigned to
brains with the most severely dysmorphic neurons. The asterisk indicates an
animal with severe dendritic pathology (2) that was unable to perform on
the rotarod because it developed seizures when it was tested. There is a
significant correlation between higher degrees of dysmorphic changes and
lower RR scores ( p  0.0001).
Figure 5. Striatum of HD mice. a, Presymptomatic HD100 mouse (L46,
5 months, normal behavior) shows diffuse nuclear labeling in medium-
sized striatal neurons, which was not seen in wild-type or HD18 mice. b,
c, Severely affected HD46 mouse (L14, 14 months, RR  14, clasp,
hypoactive, broad-based gait) shows marked shrinkage of striatal neurons
in b (compare with a). Atrophy of the striatum shown in c is comparable
with grade 2 brain in Huntington’s disease. d, Nuclear inclusion (arrow)
and marked perinuclear accumulation of huntingtin appear in large
striatal neuron from HD100 mouse (L46, 5 months, RR  96, clasp). e,
f, Nuclear inclusions (arrows) detected with anti-ubiquitin antibody in e
and with anti-FLAG antibody in f in medium-sized striatal neurons of
affected HD100 mouse (L63, 11 months,clasp, hypoactive, broad-based
gait). Immunostaining for huntingtin in a, b, and d was performed with
Ab585. Scale bars: a, b, 25 m; c, 1 mm; d, 10 m; e, f, 25 m.
Laforet et al. • Neuronal Changes and Behavior in HD J. Neurosci., December 1, 2001, 21(23):9112–9123 9117
wild-type and HD18 mice (control, 151  14.9, SE; HD, 71.3 
4.10; p  0.0003). One notable HD46 mouse with a 31% reduc-
tion in neuronal density showed marked atrophy of the striatum
characteristic of a grade 2 HD brain (Fig. 5c). Nonetheless,
stereological analysis in striatum revealed no consistent differ-
ence in HD100 compared with WT or CT18 (HD100, n  7;
CT18, n 3; WT, n 7; HD100 94% of WT and 91% of CT18
neurons per striatum; NS).
In HD mice in which changes in the cortex and striatum had
been observed, we examined the presence of nuclear changes in
huntingtin labeling in cerebellum, hippocampus, substantia nigra,
and brainstem. None of these other regions is known to be
affected in the early stages of Huntington’s disease but can be
involved at advanced stages of the disease (Vonsattel and Di-
Figlia, 1998). In 11 of 14 HD mice that were studied, nuclear
inclusions appeared in a few cells in one or more of the regions.
Diffuse nuclear labeling was not evident in neurons in any of
these regions, except for one mouse, which had the most severe
motor impairment. In this mouse (shown in Fig. 5b,c) diffuse
nuclear labeling occurred in 	25% of cerebellar Purkinje cells
and hippocampal pyramidal neurons. Thus, except for the most
severely affected mice, nuclear changes in huntingtin immunore-
activity were not prominent in other brain regions compared with
the cortex and striatum.
We compared the occurrence of different neuropathological
changes in the cortex and striatum with behavioral phenotype.
The higher the dysmorphic dendrite score (Fig. 6B; see Materials
and Methods), the worse the rotarod score ( p  0.0001) and the
greater the number of neurological deficits ( p  0.0001). In
cortex the prevalence of diffuse nuclear labeling (Fig. 6A, top)
Figure 7. Electrophysiological characteristics of striatal neurons in HD transgenic mice. A, Responses to intracellular square wave hyperpolarizing and
depolarizing current pulses in WT and HD100 striatal neurons. Amplitudes and durations of pulses are shown in the bottom traces (for clarity, the
voltage responses induced by the highest intensity pulses are not shown for WT). B, EPSPs evoked by increasing intensities of stimulation of WT and
HD100 striatal neurons. C, Input–output relationships for synaptic responses evoked in WT and HD100 striatal neurons. Each point represents the mean
intensity ( SE) to evoke synaptic responses that were 20, 50, and 80% of the maximum amplitude. D, Responses to NMDA. Peak currents (lef t), current
densities (middle), and the percentage of changes in intracellular Ca 2 (right) in WT (n  6 neurons, 3 WT mice) and HD100 mice (n  14 neurons,
4 HD mice) after stimulation of striatal neurons with 50 M NMDA. Values are means and SE. Asterisk denotes p 0.05 for peak current and current
density and p  0.025 for Ca 2, using Welch’s approximation to the t test (Welch, 1947). E, Current density–voltage relationships in response to a ramp
voltage command before and after the bath application of 50 M NMDA in HD100 (n  5) and WT (n  5) striatal neurons. Current density–voltage
relationships were calculated as the response to the agonist minus a baseline response in the absence of the agonist. NMDA current densities were
significantly larger in transgenic than in control animals from 50 to 10 mV ( p  0.05). F, Time course of changes in mean NMDA-induced current
densities ( SE). HD100 group was divided into least- and most-affected neurons (see Results for details and justifications). Asterisks in F and G indicate
that the most-affected HD100 group was significantly different from its respective WT and least-affected HD100 group ( p  0.05). The horizontal line
indicates the application of NMDA in F and G. G, Time course of mean percentage of changes ( SE) in Ca 2 concentration in most- and least-affected
HD100 and WT neurons.
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correlated with worse rotarod scores (Pearson correlation coeffi-
cient, r  0.74; p  0.03) and a higher number of neurological
deficits (r  0.79; p  0.002). In contrast, diffuse nuclear labeling
in striatal neurons did not predict neurological impairments (r 
0.44 for rotarod and r 0.41 for number of deficits; both NS). The
frequency of nuclear inclusions (Fig. 6A, bottom) was not associ-
ated with worse rotarod scores in either brain region, but in cortex
it was correlated with better rotarod performance (r  0.74; p 
0.004). Shrinkage and loss of neurons in cortical layer 6 also did
not appear to correlate with rotarod performance, although these
were not quantified.
Thus we found that the mutant huntingtin transgene led to
multiple neuropathological changes in neurons in the striatum
and cortex. In addition to the striatum, the cortex was a site of
early and progressive neuropathology in the HD mice. Two
findings, the extent of dendritic abnormalities revealed by exten-
sive cytoplasmic labeling and diffuse nuclear localization of hun-
tingtin in cortical neurons, were the most predictive of the degree
of neurological impairment. In contrast, the formation of
huntingtin-positive nuclear inclusions had no predictive value.
Impaired responsiveness to corticostriatal stimulation
correlates with alterations in dendrite morphology
Striatal neurons from WT (n  13) and HD100 mice (n  12)
showed similar intracellular responses to current injections (Fig.
7A), with no significant differences in average resting membrane
potential (RMP) or action potential amplitudes. Mean input
resistance in the HD neurons was slightly lower than in WT
neurons (28.3  4.5 vs 40.9  4.5 M in HD100 and WT,
respectively). Stimulation of subcortical white matter corpus cal-
losum, which was in the slice preparation, evoked slightly smaller
synaptic responses (EPSPs) in striatal neurons of HD mice com-
pared with neurons of WT mice [mean amplitude and half-
amplitude duration: for HD mice, 7.3  1.3 mV and 7.9  0.4
msec; for WT mice, 7.8  1.6 mV and 8.8  0.9 msec (Fig. 7B)].
Of more importance, there was a statistically significant rightward
shift in the input–output curve, indicating that more current was
required to produce responses in neurons from HD100 mice
( p  0.05; Fig. 7C).
Striatal neurons were labeled by intracellular injection of
biocytin (Fig. 8 A,B). The labeled cells were medium sized and
displayed relatively similar spine densities in HD and WT
mice. However, neurons from HD100 mice had significantly
more dendrites with endings that curved back toward the soma
(J-dendrites) and /or had sharp bends (wavy dendrites) com-
pared with WT mice (Fig. 8 B,C). Mean J-dendrites and wavy
scores in HD mice were 1.39  0.27 and 3.32  0.23, respec-
tively, and in WT were 0.62  0.13 ( p  0.05) and 2.23  0.17
( p  0.001), respectively. In the HD mice, scores of J-
dendrites and wavy dendrites were correlated significantly with
each other (HD: r  0.589, p  0.05, n  12; WT: r  0.03,
n  13). These scores also were correlated with the amount of
current that was necessary to induce 20% of the maximum
synaptic responses (J-dendrite score vs current: r  0.87, p 
0.05, n  5; wavy dendrite score vs current: r  0.93, p  0.05,
n  5). These results indicated that altered morphology and
abnormal synaptic physiology covaried in the HD neurons.
The number of J-dendrites, but not wavy dendrites, also cor-
related with the current that was necessary to produce synaptic
responses in WT mice, suggesting that the former property
might covary with synaptic input in general.
Cortical neurons in HD and WT mice were filled with
biocytin to examine dendrite morphology. Labeled WT neu-
rons (n  3) had the typical appearance of pyramidal cells,
with an extensive basal plexus and a smooth apical dendrite
that extended toward the pia (Fig. 8 D,F ). In contrast, cortical
neurons in HD100 mice displayed dendritic abnormalities
(four of eight recovered cells; Fig. 8 E,G), including beading,
small sharp bends (n  4; Fig. 8G), and misaligned and
markedly bifurcated apical dendrites (Fig. 8 E, arrow). These
results were consistent with the dysmorphic changes seen in the
cortex of HD mice with huntingtin labeling.
Figure 8. Examples of biocytin-filled medium-sized spiny striatal neu-
rons ( A–C) and cortical neurons (D–G) in WT (A, D, F ) and HD100
mice (B, C, E, G). B, HD neuron has J-dendrites with curved endings
( filled arrowheads) and wavy dendrites with sharp bends (open arrows).
Scale bar in B also applies to A. C, High magnifications of wavy dendrites
with sharp bends (arrowheads at top and bottom lef t) and J-, or recurved,
ending (arrowhead in bottom right). D, Cortical WT neuron has smooth
dendrites and extension of the apical dendrite to the pial surface (arrow).
E, A cortical pyramidal neuron from an HD mouse with a disoriented
apical dendrite (arrow). F, Higher magnification of a cortical pyramidal
neuron in the WT mouse shown in D. Note the smooth apical dendrite
(arrow). G, Higher magnification of HD neuron shown in E (rotated to fit
better in the rectangular frame). Note the small sharp bends (arrow points
to apical dendrite). Scale bar in E also applies to D.
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Response to NMDA receptor activation is altered in
striatal neurons of HD100 mice
Excitotoxicity may contribute to neuronal death in HD and other
neurodegenerative disorders and may involve alterations in
NMDA-type glutamate receptors and a rise in intracellular Ca2
(Coyle and Schwarcz, 1976; McGeer and McGeer, 1976; Choi,
1988; DiFiglia, 1990; Beal et al., 1991; Albin and Greenamyre,
1992; Brown et al., 1997). We examined electrophysiological
properties of NMDA receptors in neurons from striatal slices of
WT and HD100 mice. Peak membrane currents, regardless of
time, induced by the activation of NMDA receptors were evalu-
ated with whole-cell voltage-clamp recording (see Materials and
Methods). Peak membrane currents induced by NMDA (50 M,
3 min duration) were significantly larger in HD100 mice (n  14
neurons) compared with wild-type controls (n  6 neurons; p 
0.05; Fig. 7D). To normalize for cell size, we determined NMDA
current density (peak current divided by cell capacitance; Alz-
heimer et al., 1993). HD mice displayed significantly increased
NMDA peak current density compared with WT ( p  0.05;
Fig. 7D).
In a subgroup of neurons from HD100 (n  5) and wild-type
controls (n  5) we evaluated possible changes in voltage depen-
dence. NMDA currents were examined with a ramp protocol
[voltage command from 70 to 30 mV (5 sec) and then back to
90 mV (1 sec); all data were collected from the downward ramp]
before and after bath application of NMDA. Current density–
voltage relationships were calculated as the response to the ago-
nist minus a baseline response in the absence of the agonist. We
found that NMDA current densities were significantly larger in
transgenic than in control animals from 50 to 10 mV ( p 
0.05; Fig. 7E). Both groups displayed peak current densities
between 30 and 20 mV; no obvious changes in voltage depen-
dence were apparent.
Finally, we evaluated intracellular Ca2 flux induced by expo-
sure to NMDA, using fura-2 as a Ca2 indicator. Basal Ca2
levels were not statistically different between HD100 and WT.
However, with treatment with NMDA, Ca2 influx was signifi-
cantly greater in HD100 mice than in WT mice ( p  0.025; Fig.
7D). In HD100 mice two populations of cells emerged: one
population with peak NMDA currents and densities very similar
to those obtained from WT animals and a second population of
neurons with much higher peak currents and current densities.
Seven of 14 neurons in the HD100 mice accounted for the
marked increase in NMDA peak currents and current density by
displaying changes that were three- to sixfold greater than the
other neurons, which had values similar to WT. Because there
appeared to be two populations of neurons in HD100 mice, we
divided these neurons into two groups (most-affected and least-
affected neurons) to analyze the time course of the effects of the
NMDA application. Current density was increased significantly
only in the most-affected neurons from 3 to 7 min after NMDA
application ( p  0.05; Fig. 7F). Although there was considerable
cell-to-cell variation, the most-affected neurons displayed signif-
icantly larger increases in intracellular Ca2 from 4 to 5 min after
NMDA application ( p  0.05; Fig. 7G). Thus the presence of
electrophysiological abnormalities in response to NMDA was
marked but variable in the HD100 mice, thereby defining a
subpopulation of neurons more affected by the transgene. More-
over, neurons with altered response to NMDA occurred in an
HD100 mouse with no deficits and in two HD100 mice with
motor impairments (one with hyperactivity and one with hyper-
activity and clasp). This finding suggests that altered function of
NMDA receptors in striatal neurons may precede the onset of
motor deficits. Unfortunately, the morphology of striatal neurons
with altered NMDA receptor function could not be evaluated
with biocytin because of the presence of the Ca2 indicator
fura-2. Because NMDA was applied in the bath and the changes
were examined over an 8 min period during and after application
of the agonist, it is conceivable that the observed effects were
attributable to a combination of NMDA receptor activation as
well as changes in receptor desensitization, inactivation, or
rundown.
DISCUSSION
We sought to identify critical neuropathological and functional
neuronal changes that explain the onset and progression of the
Huntington’s disease phenotype. We used heterozygote trans-
genic mice that express a large N-terminal fragment of the human
huntingtin gene with normal or expanded CAG repeats. Trans-
fection of this size of mutant human huntingtin in clonal striatal
cells recapitulates in vitro many of the subcellular neuronal
changes in Huntington’s disease brain (Kim et al., 1999; Sapp et
al., 1999; Kegel et al., 2000). In transgenic HD mice we found that
nuclear inclusion formation alone is insufficient to cause the
aberrant phenotype; instead, abnormal dendritic morphology and
diffuse nuclear labeling in cortex are aligned with behavioral
changes. Furthermore, the size of huntingtin expressed in our
transgenic HD model (1000 amino acids) with expanded polyglu-
tamines suffices to cause the neuropathological changes found in
Huntington’s disease. We propose that cortical involvement in
our HD transgenic mice, as corroborated by neuropathological
and electrophysiological findings, contributes to the development
of phenotype in the HD mice. We speculate that cortical changes
in the human are fundamental to the onset and progression of
phenotype in Huntington’s disease.
Abnormal neuronal morphology and diffuse nuclear huntingtin
in the cortex predict the presence of clinical disease in our
transgenic HD mice. In contrast, nuclear accumulation of hun-
tingtin in the striatum is comparable in HD mice regardless of the
severity of motor deficits. This characteristic of striatal neuropa-
thology can occur early and might contribute to the clinical
course, but it is insufficient to predict the onset of behavioral
deficits. Striatal neurons from HD mice displayed abnormal elec-
trophysiological responses to cortical stimulation and to NMDA
receptor activation. These abnormal responses were separate
from the extent of neurological impairment. Thus, even before
the onset of outward phenotype, mutant huntingtin could affect
cortical inputs to the striatum and thereby alter function in
corticostriatal pathways.
Although Huntington’s disease often has been considered pri-
marily a process of striatal neurodegeneration, there have been
indications that the cortex contributes to the disease diathesis and
that mutant huntingtin affects corticostriatal circuitry early in the
disease. Marked nuclear and cytoplasmic accumulation of mutant
huntingtin in cortical pyramidal neurons coincides with dendritic
abnormalities in postmortem brain of patients with low-grade
striatal pathology (DiFiglia et al., 1997; Sapp et al., 1997). Fur-
thermore, abundant (mutant) huntingtin is evident in numerous
cortical dystrophic axons that project to the striatum (Sapp et al.,
1999). In Golgi impregnations the cortical neurons as well as the
striatal neurons show abundant dendritic changes in Huntington’s
disease postmortem brain (Graveland et al., 1985; Sotrel et al.,
1993). Clinical findings also implicate cortical involvement. Met-
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abolic dysfunction in cortex can occur early in the course of the
disease (Sax et al., 1996), and cognitive disturbances can appear
before motor deficits (Lawrence et al., 1996). In a “knock-in”
model of Huntington’s disease in which an expanded N-terminal
region of mutant huntingtin was inserted into murine huntingtin,
behavioral changes were not observed despite the presence of
nuclear inclusions in the striatum (Wheeler et al., 2000). The mice
had no neuronal changes in the cortex. In contrast, Lin et al.
(2001) generated a knock-in mouse with 150 CAG repeats that
exhibited predominantly striatal huntingtin nuclear inclusions
with a modicum of cortical involvement. These animals developed
late-onset behavioral changes. In all, these findings support the
centrality of the cortex in the genesis of the Huntington’s disease
phenotype.
Use of the neuron-specific enolase promoter directed transgene
expression to neurons. Endogenous huntingtin was detected in
neurons and eluded detection by immunohistochemistry in glia.
Similarly, huntingtin mRNA was found in high abundance by in
situ hybridization (Landwehrmeyer et al., 1995) in neurons but in
very low amounts in glia. A primary dysfunction of glia in Hun-
tington’s disease has been proposed on the basis of neuropatho-
logic grade-dependent changes in the astrocyte-specific GLT1
glutamate transporter (Arzberger et al., 1997). Reactive astrocy-
tosis is a feature of striatal pathology in Huntington’s disease and
a criterion for the grading system of striatal pathology (Vonsattel
et al., 1985). How the expression of mutant huntingtin in glia
might contribute to astroglial changes in Huntington’s disease
brain is unclear.
Our results in transgenic HD mice support in vitro data (Sau-
dou et al., 1998; Kim et al., 1999) that nuclear inclusions do not
play an early or decisive role in cell death. In a conditional mouse
model of HD involving highly expanded CAG repeats in exon 1
of huntingtin, Yamamoto et al. (2000) showed that the formation
of nuclear inclusions in the striatum was reversible with the
transcriptional repression of the transgene. Therefore, the initial
accumulation of mutant huntingtin in inclusions did not trigger
inexorable cell death. Our findings indicate that cellular dysfunc-
tion in Huntington’s disease might require an accumulation of
mutant huntingtin over a long duration, thus also extending
therapeutic opportunities.
Electrophysiological data obtained in slice preparations from
HD100 mice demonstrated that striatal neurons had an altered
response to cortical stimulation and NMDA receptor activation
but a normal average resting membrane potential and action
potential amplitudes. These results indicate a fundamental defect
in NMDA receptor function. We found that striatal neurons in
R6/2 mice with huntingtin exon 1 transgene (Mangiarini et al.,
1996) also displayed altered responses to NMDA receptor acti-
vation (Cepeda et al., 2000) and to cortical stimulation (Levine et
al., 1999; Klapstein et al., 2000). However, the presence of depo-
larized resting membrane potentials in these cells makes it diffi-
cult to interpret the significance of changes in NMDA receptor
responsiveness.
The marked changes in dendritic architecture (J- and wavy
dendrites) observed in cortical and striatal neurons of the HD100
mice could contribute to the reduced synaptic responsiveness of
striatal neurons to cortical stimuli. In cortical neurons the alter-
ations in dendritic geometry and the distribution of ion channels
significantly influence neuronal firing patterns, especially those
dependent on glutamatergic neurotransmission (Henze et al.,
1996; Mainen and Sejnowski, 1996).
Excitotoxicity as a mechanism for the pathogenesis of Hun-
tington’s disease has been posited previously (Coyle and
Schwarcz, 1976; DiFiglia, 1990; Albin and Greenamyre, 1992). In
vivo treatment of rat striatum with quinolinic acid, an NMDA
receptor agonist, created a pattern of cell loss reminiscent of
Huntington’s disease (Beal et al., 1991). We found that NMDA
receptor activation significantly elevated peak current densities
and levels of intracellular Ca2 in striatal neurons of HD100
mice compared with wild-type mice. The latter effect could lower
the threshold for excitotoxic injury. In addition, cell swelling, an
early event in the excitotoxic cascade (Choi, 1988), is seen in
some neurons from HD100 mice after the application of NMDA
in vitro (M. Levine, unpublished observations). Similar findings
have been observed in striatal cells from transgenic mice with
huntingtin exon 1 (R6/2) and a knock-in HD mouse with no
behavioral phenotype (Levine et al., 1999).
In other experimental systems the expression of mutant hun-
tingtin has been shown to alter electrophysiological properties
mediated by NMDA receptor activation and to render cells more
susceptible to excitotoxicity-related cellular changes. Coexpres-
sion of NMDA receptor subtypes NR1 and NR2B with mutant
huntingtin into human embryonic kidney cells produced larger
currents after NMDA receptor activation than did coexpression
of these receptors with wild-type huntingtin (Chen et al., 1999)
and increased excitotoxic cell death (Zeron et al., 2001). Current
studies indicate that NMDA receptor activation is excitotoxic in
our HD100 and HD46 mice (A. Petersen, K. Chase, Z. Pusch-
ban, M. DiFiglia, P. Brundin, and N. Aronin, unpublished data).
Unexpectedly and inexplicably, striatal neurons in the R6/2 mice
are resistant to the neurotoxic effects of quinolinic acid (Hansson
et al., 1999).
Caveats understandably attend the use of transgenic models.
Different promoters, transgene size, CAG repeat length, and
genetic background might influence characteristics of particular
models. Our murine model used a large portion of mutant
N-terminal huntingtin; exon 1 and full-length huntingtin have
provided inadequate neuropathology to pursue our goals. Most
huntingtin transgenics use promoters that are foreign to mice
[portions of human (Mangiarini et al., 1996); CMV-based (Reddy
et al., 1998); human YAC (Hodgson et al., 1999); prion-based
(Schilling et al., 1999)]. We used a neuron-specific promoter that
by mRNA estimations regulated mutant huntingtin gene expres-
sion differently from endogenous huntingtin gene expression but
provided morphologic changes in neurons that are characteristic
of Huntington’s disease. Finally, several mouse strains have been
used in generating HD models. Ours has a mixed background of
two strains. With nearly 500 mice tested in multiple lineages, we
suggest that the mutant huntingtin, rather than clustered strain
differences, accounts for our observed motor impairments. Fur-
thermore, preliminary studies in our laboratory indicate that
transgenic mice with full-length huntingtin HD100 in C57BL/6
develop behavioral abnormalities at the same age as HD100
transgenic mice with N-terminal one-third of the protein in
C57BL/6SJL.
Our findings point to a multi-tiered process of dysfunction in
cortical and striatal neurons; this process produces the HD mouse
phenotype. Accumulation of mutant huntingtin in nuclear and
cytoplasmic compartments occurs contemporaneously with the
onset of behavioral abnormalities as detected in our transgenic
HD mice. Dendritic pathology in the cortex, electrophysiological
abnormalities in the striatum, and disruption of corticostriatal
circuitry were detected in mice at early and later times. Accumu-
lated mutant huntingtin might maintain the neuron in a state of
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chronic vulnerability. Cortical and striatal neurons respond to the
persistent presence of mutant huntingtin in a highly reproducible
pattern by forming J- and wavy dendrites. How mutant huntingtin
causes J- and wavy dendrites is unknown, but effects of the
mutant protein on the cytoskeleton and vesicle trafficking could
be implicated in altering dendritic architecture (Aronin et al.,
1999). Striatal neurons in our HD mice concurrently become
especially sensitive to NMDA receptor activation and Ca2 flux
into the neuron increases. Collectively, these quantifiable char-
acteristics of the HD mouse phenotype should be valuable in
identifying therapeutic approaches that slow or reverse neuronal
dysfunction.
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